Sarah Ross, DO
Geriatric Medicine · Fort Worth, TXNPI 1912162157
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.2% of the total across 104 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 31 manufacturers, the largest accounting for just 18.0% — the pattern of someone who eats at a lot of different presentations.
Across 104 payments — averaging $19.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$371
- Eisai Inc.$256
- Lilly USA, LLC$202
- Teva Pharmaceuticals USA, Inc.$147
- Mylan Specialty L.p.$128
- GSK$123
- plus $837 from 25 others
What the payments were for
- Speaking & faculty fees$161%
- Food & beverage$2,04799%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 21 | $371 |
| Eisai Inc. | 10 | $256 |
| Lilly USA, LLC | 11 | $202 |
| Teva Pharmaceuticals USA, Inc. | 7 | $147 |
| Mylan Specialty L.p. | 5 | $128 |
| GSK | 7 | $123 |
| Neurocrine Biosciences, Inc. | 4 | $89 |
| Biogen | 5 | $86 |
| Abbott | 4 | $86 |
| Inspire Medical Systems, Inc. | 1 | $85 |
| Amgen | 1 | $81 |
| Novartis | 4 | $52 |
| Acadia Pharmaceuticals Inc | 2 | $30 |
| Astellas Pharma US Inc | 2 | $29 |
| Pfizer | 2 | $28 |
| Boehringer Ingelheim | 2 | $28 |
| Johnson & Johnson | 2 | $23 |
| Argenx US, Inc. | 1 | $23 |
| UCB, Inc. | 1 | $19 |
| Sumitomo Pharma America, Inc. | 1 | $19 |
| Bayer | 1 | $18 |
| Acorda Therapeutics, Inc | 1 | $16 |
| C2n Diagnostics, LLC | 1 | $16 |
| Sun Pharmaceutical Industries Inc. | 1 | $16 |
| AbbVie | 1 | $15 |
| Dexcom, Inc. | 1 | $14 |
| Ultragenyx Pharmaceutical Inc. | 1 | $14 |
| Exact Sciences | 1 | $14 |
| Radius Health, Inc. | 1 | $13 |
| Avanir Pharmaceuticals, Inc. | 1 | $13 |
| Philips North America LLC | 1 | $12 |
How this compares
$2,063 in reported general payments places this provider in the 85th percentile of 275 geriatric medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 35 | $31,012 |
| JanuviaSitagliptin Phosphate | 24 | $23,436 |
| GemtesaVibegron | 27 | $20,798 |
| TrulicityDulaglutide | 17 | $13,877 |
| Memantine Hcl | 184 | $10,459 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 15 | $10,271 |
| Rivastigmine | 45 | $8,162 |
| Divalproex Sodium | 64 | $5,124 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 103 | $3,500 |
| MresviaRsv Vaccine, Pref, Mrna/Pf | 11 | $3,408 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 18 | $3,107 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 14 | $2,471 |
| Trazodone Hcl | 179 | $2,447 |
| Levothyroxine Sodium | 191 | $2,417 |
| Sertraline Hcl | 201 | $2,235 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $28 | $31,01235 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $19 | $20,79827 claims |
| Lilly USA, LLCTrulicity | $202 | $13,87717 claims |
| GSKTrelegy Ellipta | $123 | $10,27115 claims |
| AbbVieSynthroid | $15 | $1,08920 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 275 geriatric medicine providers in Texas.
Other geriatric medicine in Fort Worth
- Ryan ChoudhuryFort Worth$4K
- Melissa HudsonFort Worth$2K
- Brittany LoveFort Worth$2K
- Valerie AgenaFort Worth$1K
- Mauricio Gonzalez-AriasAustin$825K
- Eberenne IgbokwePearland$124K
- Diana KerwinDallas$81K
- David SmithBrownwood$19K
- Alejandro ArizmendiHelotes$15K
- Rosa VizcarraSan Antonio$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.